Results 21 to 30 of about 118,423 (273)

Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001. [PDF]

open access: yes, 2016
Neuroendocrine tumors (NETs) are grouped together as a single class on the basis of histologic appearance, immunoreactivity for the neuroendocrine markers chromogranin A and synaptophysin, and potential secretion of hormones, neurotransmitters ...
Brzezniak, Christina   +11 more
core   +4 more sources

Malignancy within a tail gut cyst:a case of retrorectal carcinoid tumour [PDF]

open access: yes, 2014
Purpose. Tailgut cysts with malignant transformation are rare entities. We discuss the diagnostic strategy and treatment of a malignancy within a tailgut cyst. Methods.
Abukar, A. A.   +7 more
core   +7 more sources

Gel chromatographic characterization of immunoreactive adrenocorticotropin in patients with ACTH hypersecretion [PDF]

open access: yes, 1989
We investigated the molecular size of circulating immunoreactive ACTH by gel chromatography in patients with ACTH hypersecretion due to various disorders of the hypothalamic-pituitary-adrenal axis.
A Chatelain   +19 more
core   +1 more source

Primary Mesenteric Carcinoid Tumor Presenting with Carcinoid Syndrome

open access: yesCase Reports in Gastroenterology, 2018
Neuroendocrine neoplasms (NENs) are a diverse group of tumors arising throughout the body with a common origin from neuroendocrine cells. Well-differentiated NENs, also known as neuroendocrine tumors (NETs), are generally indolent and are often found ...
Oluwaseun Shogbesan   +3 more
doaj   +1 more source

Gastrointestinal carcinoid tumors [PDF]

open access: yesRevista Española de Enfermedades Digestivas, 2010
carcinoid tumors (CTs) represent the commonest neuroendocrine tumors. Those in the gastrointestinal tract are diagnosed in surgical specimens, clinically, and using imaging techniques (endoscopy, echoendoscopy, CT, Octreoscan, etc.). The goal of this retrospective study was to review a personal series of gastrointestinal carcinoid tumors, and to ...
Varas Lorenzo, M. J.   +3 more
openaire   +4 more sources

Fine needle aspiration cytology of hepatic metastases of neuroendocrine tumors: A 20‐year retrospective, single institutional study [PDF]

open access: yes, 2017
Background Fine needle aspiration (FNA) is considered an excellent technique for documenting metastatic neuroendocrine tumors (NETs). This study aims to evaluate the accuracy of FNA in diagnosing metastatic NETs to the liver and determining the grade ...
Cramer, Harvey   +3 more
core   +1 more source

Pioglitazone inhibits growth of carcinoid cells and promotes TRAIL-induced apoptosis by induction of p21(waf1/cip1) [PDF]

open access: yes, 2001
Background/Aims: We investigated the effect of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist pioglitazone on growth and TRAIL-induced apoptosis in carcinoid cells.
Chen, Youhai   +4 more
core   +1 more source

Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors [PDF]

open access: yes, 2015
Over the past few years, knowledge regarding the molecular pathology of sporadic pancreatic neuroendocrine tumors (PNETs) has increased substantially, and a number of targeted agents have been tested in clinical trials in this tumor type.
Ahn   +64 more
core   +1 more source

Transanal minimally invasive surgery for rectal lesions [PDF]

open access: yes, 2016
Background and Objectives: Transanal minimally invasive surgery (TAMIS) has emerged as an alternative to transanal endoscopic microsurgery (TEM). The authors report their experience with TAMIS for the treatment of mid and high rectal tumors.
Balla, Andrea   +7 more
core   +1 more source

Heterogeneous tumor‐immune microenvironments between primary and metastatic carcinoid tumors differentially respond to anti‐PD‐L1 antibody therapy

open access: yesThoracic Cancer, 2021
A pulmonary carcinoid tumor is a rare tumor that lacks a validated therapeutic approach for unresectable disease. Understanding the intersite tumor‐immune heterogeneity is essential to harness the immune system for cancer therapy.
Shinya Sakata   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy